NasdaqCM - Delayed Quote • USD
Capricor Therapeutics, Inc. (CAPR)
At close: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.11 | -0.29 | -0.96 | 0.1 |
| Low Estimate | -0.26 | -0.32 | -1.36 | -1.21 |
| High Estimate | 0.03 | -0.26 | -0.75 | 1.44 |
| Year Ago EPS | -0.31 | -0.29 | -0.83 | -0.96 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 9.7M | 4.41M | 28.53M | 119.36M |
| Low Estimate | 5M | 3.92M | 27.2M | 22.5M |
| High Estimate | 14.1M | 5M | 30M | 185M |
| Year Ago Sales | 2.99M | 3.92M | 25.18M | 28.53M |
| Sales Growth (year/est) | 224.80% | 12.60% | 13.30% | 318.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.32 | -0.35 | -0.29 | -0.09 |
| EPS Actual | -0.31 | -0.29 | -0.25 | -0.02 |
| Difference | 0.01 | 0.06 | 0.04 | 0.07 |
| Surprise % | 3.10% | 17.10% | 13.80% | 77.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.29 | -0.96 | 0.1 |
| 7 Days Ago | -0.11 | -0.29 | -0.96 | 0.1 |
| 30 Days Ago | -0.11 | -0.29 | -0.96 | 0.1 |
| 60 Days Ago | -0.3 | -0.3 | -1.05 | -0.49 |
| 90 Days Ago | -0.3 | -0.3 | -1.05 | -0.49 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CAPR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 64.50% | -- | -- | 2.60% |
| Next Qtr. | 0.00% | -- | -- | 13.40% |
| Current Year | -15.70% | -- | -- | 5.20% |
| Next Year | 110.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/25/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 1/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/4/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/16/2023 |
Related Tickers
ACXP Acurx Pharmaceuticals, Inc.
2.0200
-0.49%
BNTC Benitec Biopharma Inc.
6.94
+3.27%
ALRN Aileron Therapeutics, Inc.
5.0000
+0.20%
MDNAF Medicenna Therapeutics Corp.
1.4000
+0.72%
HOOK HOOKIPA Pharma Inc.
0.8061
-5.16%
ELDN Eledon Pharmaceuticals, Inc.
2.0200
+2.54%
NGENF NervGen Pharma Corp.
1.5000
-1.96%
CYCC Cyclacel Pharmaceuticals, Inc.
1.6000
-29.82%
ABEO Abeona Therapeutics Inc.
3.1900
+0.63%
ANL Adlai Nortye Ltd.
13.46
-0.66%